×
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

India seeks remdesivir, oxygen from EU, aid expected soon

The EU spokesman added that so far, among EU states, Ireland has offered to send oxygen, which is crucial for patients with breathing problems
Last Updated : 26 April 2021, 12:51 IST
Last Updated : 26 April 2021, 12:51 IST

Follow Us :

Comments

India has asked the European Union to send medical oxygen and Gilead's antiviral drug Remdesivir to fight a surge in Covid-19 cases, an EU official said on Monday, adding that the aid could be made available soon.

India's new coronavirus infections hit a record high for a fifth straight day on Monday, as countries around the world pledged to send urgent medical aid to help battle the crisis overwhelming its hospitals.

"The Indians have asked for medical oxygen and antivirals, notably Remdesivir," a spokesman for the EU Commission told a news conference.

The EU signed a contract in October with Gilead which allowed its 27 member states and 10 partner countries including Britain to order up to 500,000 Remdesivir courses over six months.

However, it is unclear how many doses have actually been bought by EU states after a trial conducted by the World Health Organization suggested Remdesivir had little or no effect on mortality or length of hospital stays among patients with the respiratory disease.

The drug is considered more effective for patients in less serious conditions.

The EU spokesman added that so far, among EU states, Ireland has offered to send oxygen, which is crucial for patients with breathing problems, while Germany and France have also indicated they will help.

"We can expect that in the next hours and days we can confirm more help," the spokesman added.

Asked about whether the EU would limit flights from India, the spokesman said the EU continued to discourage non-essential travel to and from third countries.

ADVERTISEMENT
Published 26 April 2021, 12:51 IST

Deccan Herald is on WhatsApp Channels | Join now for Breaking News & Editor's Picks

Follow us on :

Follow Us

ADVERTISEMENT
ADVERTISEMENT